Aakaar Medical FY26 PAT rises 10% to ₹6.63 crore
Aakaar Medical Technologies Limited reported a 10% increase in Profit After Tax (PAT) to ₹6.63 crore for the financial year ended March 31, 2026, on revenue of ₹66.96 crore. The Board has proposed an Employee Stock Option Plan (ESOP) for up to 11,33,825 options and an increase in authorised share capital to ₹15.40 crore, subject to shareholder approval at the AGM on June 30, 2026.
*this image is generated using AI for illustrative purposes only.
Aakaar Medical Technologies Limited reported a 10% increase in Profit After Tax (PAT) to ₹6.63 crore for the financial year ended March 31, 2026, on revenue of ₹66.96 crore. The company maintained its profitability track record for the tenth consecutive year, with EBITDA for the period standing at ₹10.97 crore. The Board of Directors has recommended an Employee Stock Option Plan (ESOP) and an increase in authorised share capital, which will be placed before shareholders for approval at the upcoming Annual General Meeting (AGM).
Financial Performance
The company’s revenue from operations increased to ₹66.96 crore in FY26 from ₹61.58 crore in the previous year. Profit Before Tax (PBT) stood at ₹9.19 crore, compared to ₹8.11 crore in FY25. The EBITDA margin improved to 16.39% from 15.94% in the previous year. The cash and bank balance as of March 31, 2026, was recorded at ₹16.24 crore.
| Financial Metric | FY26 (₹ in crore) | FY25 (₹ in crore) |
|---|---|---|
| Revenue from Operations | 66.96 | 61.58 |
| Profit Before Tax | 9.19 | 8.11 |
| Profit After Tax | 6.63 | 6.03 |
| EBITDA | 10.97 | 9.81 |
Strategic Resolutions
The Board has proposed several key resolutions for shareholder approval at the 13th AGM scheduled for June 30, 2026. A Special Resolution seeks approval for the 'Aakaar Medical Technologies Employees Stock Option Plan 2026'. The plan proposes granting up to 11,33,825 stock options, representing not more than 8% of the outstanding equity shares, to eligible employees and directors. The options will be exercisable into fully paid-up equity shares of ₹10 each.
Additionally, an Ordinary Resolution proposes increasing the authorised share capital from ₹15 crore to ₹15.40 crore by creating 4,00,000 additional equity shares of ₹10 each. This increase is intended to accommodate the issuance of ESOPs. The Board has also recommended the re-appointment of Shri Dilip Ramesh Meswani, Director retiring by rotation, and the appointment of M/s NAM & Associates as Secretarial Auditors for a term of five years commencing FY 2026-27.
Operational Highlights
During the year, the company expanded its customer base to over 6,300 doctors and clinics. The own-brand portfolio contributed 37% to the total revenue, supporting margin expansion. The company also launched several high-potential products, including Letybo, Saypha, and the VM Corp exosome suite, strengthening its position in the regenerative aesthetics segment. The IPO proceeds were utilized for working capital requirements, with ₹9.35 crore deployed till March 31, 2026.
Historical Stock Returns for Aakaar Medical Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.20% | -14.64% | +29.54% | -7.35% | -1.82% | -1.82% |
How will the dilution from the proposed ESOP issuance impact earnings per share for existing shareholders?
What is the company's strategy to sustain margin expansion beyond the current 37% contribution from the own-brand portfolio?
With ₹16.24 crore in cash reserves, does Aakaar plan to pursue acquisitions or further R&D in the regenerative aesthetics segment?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
